L2 Asset Management LLC Buys Shares of 10,732 United Therapeutics Corporation $UTHR

L2 Asset Management LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, HoldingsChannel reports. The firm purchased 10,732 shares of the biotechnology company’s stock, valued at approximately $5,815,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Partners Capital Investment Group LLP bought a new stake in shares of United Therapeutics in the 2nd quarter valued at $1,691,000. Whalen Wealth Management Inc. acquired a new stake in shares of United Therapeutics during the second quarter worth $512,000. Trail Ridge Investment Advisors LLC bought a new position in United Therapeutics during the second quarter worth $1,300,000. Cibc World Market Inc. bought a new position in United Therapeutics during the second quarter worth $769,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in United Therapeutics in the second quarter valued at $4,153,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In related news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $23,631,280.08. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $518.39, for a total value of $4,924,705.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $168,188,006.77. This trade represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 434,075 shares of company stock valued at $233,942,595. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Trading Down 0.0%

NASDAQ:UTHR opened at $512.88 on Tuesday. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35. The stock has a market capitalization of $22.00 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 1.74 and a beta of 0.59. The firm has a fifty day simple moving average of $532.35 and a two-hundred day simple moving average of $538.04.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.41 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of research analyst reports. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.